Fig 1: The proposed path diagram of the implied regression models fitted well in the parsimonious model (a) and just identified confirmatory multi-regression model (b) to show the contribution of folate and cobalamin with plasma Angiopoietins. Maximum likelihood estimation was performed to test the fitting function or estimation procedure of parameters in models. The plasma ANG-2 was weighted with interindividual levels of plasma VEGF-C. Rectangles were observed variables. Ellipses were latent (construct) variables. Values on the single-headed arrows (recursive) were standardized regression weights. Values on the double-headed arrows (nonrecursive) were beta (ß) of intercorrelation between two variables. Each observed indicator included in models with measurement errors (e) and residual errors (top right corner of the rectangle) to predict the latent variable. Factor loading of a link between indicator and construct (latent) was also estimated. An asterisk (*) is shown to express critical ration (CR) >1.96 of estimated ß, which means that the path (parameter) is significant at p < 0.05.
Fig 2: The effects of folic acid treatments in MCF-7 cells on expression levels of tested genes (ANGPT1, ANGPT2, VEGF, and Tie-2) relative to HGPRT as an internal control. Mean value of relative expression at each concentration of folic acid were represented at mean ± S.D. and compared using ANOVA followed by Dunnett analysis. (*p < 0.05 considered statistically significant).
Fig 3: Plasma levels of angiogenic markers, folate and cobalamin were compared with the upper limit of the normal range measured in healthy individuals (a,b). Normal ranges were ascribed as follows: ANG1 0.600–6.000 ng/ml, ANG2 0.500–3.000 ng/ml, Tie2 10–92 ng/ml, VEGF-C 0.0–0.50 ng/ml, folate 2–20 ng/ml and cobalamin 200–900 pg/ml according to protocol of kits (folate: Cat N. 7525-300 and cobalamin: Cat N. 7526-300)47,52. *p < 0.05. Mean values ± S.D. are presented.
Supplier Page from CUSABIO Technology LLC for Human Angiopoietin 2,ANG-2 ELISA Kit